Featured Research

from universities, journals, and other organizations

University Of Pittsburgh Researchers Identify Immune System Process That Could Halt Progress Of Cirrhosis In Humans

Date:
April 19, 1999
Source:
University Of Pittsburgh Medical Center
Summary:
Results of animal laboratory studies conducted at the University of Pittsburgh's Thomas E. Starzl Transplantation Institute dispel the notion that interleukin-6 (IL-6) causes liver fibrosis or cirrhosis and instead suggest that it is important to the liver's recovery. So encouraged is the research team by these findings, being presented at today's sessions of Experimental Biology '99, that it plans to initiate further studies to determine if IL-6 can slow liver disease progression in patients.

WASHINGTON, D.C., April 18 -- Results of animal laboratory studies conducted at the University of Pittsburgh's Thomas E. Starzl Transplantation Institute dispel the notion that interleukin-6 (IL-6) causes liver fibrosis or cirrhosis and instead suggest that it is important to the liver's recovery. So encouraged is the research team by these findings, being presented at today's sessions of Experimental Biology '99, that it plans to initiate further studies to determine if IL-6 can slow liver disease progression in patients.

IL-6 is a cytokine, a chemical substance secreted by immune system cells. Because it is elevated in a number of diseases, including those of the liver, its presence has been thought to be a contributing factor to, or a feature of, the disease process. The University of Pittsburgh's research indicates the immune system's release of IL-6 must be part of an effort to preserve hepatocytes, or liver cells, and are not an accomplice to their demise. In cirrhosis, the liver becomes inflamed and takes on a lumpy appearance as hepatocytes die, but other cells, such as fibroblasts and bile duct cells, proliferate.

The Pitt researchers made their discovery, an outcome that proved their own study hypothesis wrong, after a series of experiments with groups of mice either capable or incapable of producing IL-6. A model of cirrhosis was created by tying off the common bile duct. The researchers assumed the mice that could make IL-6 would fare worse, but in fact the opposite was true. The mice that could not produce IL-6 had more pathological and clinical evidence of cirrhosis, including fewer hepatocytes and higher bilirubin levels, and had a mortality rate twice that of the IL-6-producing mice.

"IL-6 is important to maintain hepatocyte mass, liver architecture and function during persistent injury," reports Tsukasa Ezure, M.D., the study's first author.

The team is designing studies whereby adult patients with various liver diseases, including sclerosing cholangitis and biliary cirrhosis, or children with biliary atresia, would receive doses of growth factors, such as IL-6, or another substance called hepatic growth factor, to determine if the progression of their disease could be halted or even improved.

"Concerning IL-6, the concept is correct, at least in animals. We're optimistic as we initiate clinical studies, but there's always concern when you take the leap from animal laboratory to the clinical setting," says Anthony J. Demetris, M.D., senior investigator of the study, who is professor of pathology and director of transplant pathology at the University of Pittsburgh.

In addition to Drs. Ezure and Demetris, other authors include: Toshiki Sakamoto, M.D.; John G. Lunz, III; Shigeki Yokomuro, M.D.; Hirokazu Tsuji, M.D., Ph.D.; Noriko Murase, M.D.; and John J. Fung, M.D., Ph.D.


Story Source:

The above story is based on materials provided by University Of Pittsburgh Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pittsburgh Medical Center. "University Of Pittsburgh Researchers Identify Immune System Process That Could Halt Progress Of Cirrhosis In Humans." ScienceDaily. ScienceDaily, 19 April 1999. <www.sciencedaily.com/releases/1999/04/990419095549.htm>.
University Of Pittsburgh Medical Center. (1999, April 19). University Of Pittsburgh Researchers Identify Immune System Process That Could Halt Progress Of Cirrhosis In Humans. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/04/990419095549.htm
University Of Pittsburgh Medical Center. "University Of Pittsburgh Researchers Identify Immune System Process That Could Halt Progress Of Cirrhosis In Humans." ScienceDaily. www.sciencedaily.com/releases/1999/04/990419095549.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins